Publication: Etoposide sensitivity of human prostatic cancer cell lines PC-3, DU 145 and LNCaP
Loading...
Date
1999
Authors
Salido, M. ; Larran, J. ; Lopez, A. ; Vilches, J. ; Aparicio, J.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Metastatic prostatic cancer is typically
refractory to androgen ablation therapy due to the
presence of androgen-independent clones in the
neoplasia. A therapeutical approach which could
effectively control androgen-dependent and independent
cells is, thus, needed. Maybe the failure of certain cancer
cells to engage in apoptosis could explain the inherent
drug resistance of many tumors. Anyway, these cells can
retain the ability to undergo apoptosis in response to an
adequate stimulus. We tested whether etoposide, a topoisomerase
I1 inhibitor, could induce apoptosis in
androgen-dependent (LNCaP) as well as independent
(PC-3 and DU 145) human prostate cancer cell lines.
Morphological examination was performed, as it is
regarded as one of the most reliable parameters for the
detection of apoptotic changes. Complementarily,
biochemical and flow cytometric studies were also used.
Characteristical changes of apoptosis were demonstrated
in PC-3, Du 145, and LNCaP cancer cells after
treatment with etoposide. These cells, thus, retain the
ability to undergo apoptosis under adequate conditions,
in a promising approach to hormone refractory prostate
cancer therapy.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.